Search Results
Jun 17, 2026, 15:22 ET CON EDISON ENERGIZES LARGEST ELECTRIC SCHOOL BUS FLEET IN NYS FOR STUDENT TRANSPORT COMPANY GVC
beyond."GVC's depot is located along a two-mile corridor where 20 percent of the city's school buses (roughly 2,000) and 3,000 medium- and heavy-duty vehicles (MHD) are dispatched.Con Edison, with approval from the New York State Public Service Commission, is prioritizing critical
More news about: Con Edison of New York
Apr 17, 2026, 15:00 ET Meiji Holdings Co., Ltd. Highlights that Yogurt Containing Bacteria Metabolite Shows a Tendency Toward Higher Response When Added to Immune Checkpoint Inhibitor Therapy in People Living with Non-small Cell Lung Cancer
Contacts]Meiji Holdings Co., Ltd. Corporate Communications DepartmentEmail: [email protected]OmnicomEmail: [email protected]
More news about: Meiji Holdings Co Ltd
Feb 26, 2026, 10:00 ET Mountain House is a Thriving California City with New Amenities, Top-Rated Schools, Rapid Growth and New Communities on the Way
Mountain House Developers, LLC (MHD) is the master developer behind Mountain House and The Lakes at Mountain House, bringing together parks, trails, schools, and lifestyle amenities within a carefully planned framework that supports modern community living. MHD collaborates with renowned homebuilders
More news about: Mountain House Developers
Jan 30, 2026, 09:39 ET Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
with a mean reduction of 6.8 MHDs (95% CI: 5.2-8.3) from a baseline of 20.0 MHDs. Additionally, 26.1% of participants achieved >75% reduction in MHD at Month 6 (95% CI: 18.9%-35.0%). Patients also reported an average increase of 6.3 additional "good days" per month (95% CI: 4.7-7.9) compared
More news about: H. Lundbeck A/S
Jan 30, 2026, 09:35 ET Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference
with a mean reduction of 6.8 MHDs (95% CI: 5.2-8.3) from a baseline of 20.0 MHDs. Additionally, 26.1% of participants achieved >75% reduction in MHD at Month 6 (95% CI: 18.9%-35.0%). Patients also reported an average increase of 6.3 additional "good days" per month (95% CI: 4.7-7.9) compared
More news about: H. Lundbeck A/S
Sep 16, 2025, 07:00 ET ShiraTronics Announces Positive 12-Month Follow-Up Results from RELIEV-CM Pilot Study, Demonstrating Sustained Clinical Benefit with Investigational Implantable Neuromodulation Therapy for Chronic Migraine
2026." Key 12-Month Results from the RELIEV-CM Pilot Study Include: 9.6 average reduction in monthly headache days (MHD) from baseline9.6 average reduction in monthly migraine days (MMD) from baselineSustained improvements in migraine-specific quality
More news about: ShiraTronics, Inc.